Latest On Orgenesis Inc (ORGS):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-10 19:14 EST | News | Orgenesis GAAP EPS of $0.17, revenue of $7.04M | N/A |  |
| 2023-03-21 23:55 EST | News | Orgenesis Inc. (ORGS) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-21 08:24 EST | News | Orgenesis GAAP EPS of -$0.59 misses by $0.22, revenue of $36.03M beats by $5.33M | N/A | |
| 2023-02-23 18:16 EST | News | Orgenesis stock sinks ~31% after launching offering to raise $3.7M | N/A | |
| 2022-11-14 13:18 EST | News | Orgenesis (ORGS) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-10 21:30 EST | News | Orgenesis GAAP EPS of $0.05 | N/A | |
| 2022-11-07 23:02 EST | News | Orgenesis jumps 26% on $50M investment from Metalmark Capital | N/A | |
| 2022-08-17 05:22 EST | News | Orgenesis, Inc's (ORGS) CEO Vered Caplan on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-16 12:14 EST | News | Orgenesis GAAP EPS of $0.22 beats by $0.24, revenue of $7.2M beats by $0.2M | N/A | |
| 2022-03-31 15:20 EST | News | Orgenesis' (ORGS) CEO Vered Caplan on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-31 15:19 EST | News | Orgenesis to raise $14.8M in stock and warrants offering | N/A | |
| 2022-03-30 22:16 EST | News | Orgenesis GAAP EPS of -$0.74, revenue of $35.5M | N/A | |
| 2021-12-09 06:05 EST | News | Warning: ORGS is at high risk of performing badly | N/A | |
| 2021-11-07 01:11 EST | News | Orgenesis Inc. (ORGS) CEO Vered Caplan on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-04 14:18 EST | News | Orgenesis EPS beats by $0.45, misses on revenue | N/A | |
| 2021-08-24 08:18 EST | News | Orgenesis (ORGS) Investor Presentation - Slideshow | N/A | |
| 2021-08-23 13:23 EST | News | Orgenesis inks collaboration agreement with Savicell to deploy Immunobiopsy platform | N/A | |
| 2021-08-05 10:48 EST | News | Orgenesis EPS beats by $0.12, beats on revenue | N/A | |
| 2021-08-05 10:48 EST | News | Orgenesis jumps 8% on Q2 beat; top-line grew six-fold with POCare Platform gaining traction | N/A | |
| 2021-05-07 13:24 EST | News | Orgenesis posts four-fold revenue growth in Q1, shares rise 11% | N/A | |
| 2021-05-06 17:03 EST | News | Orgenesis gets FDA IDE approval for Tissue Genesis Icellator COVID-19 study | N/A | |
| 2021-04-30 16:40 EST | News | Orgenesis shares rise after Bambino Gesù Children's Hospital collaboration | N/A | |
| 2021-03-19 00:22 EST | News | Orgenesis collaborates with MIDA to establish point-of-care centers at hospitals and medical institutions | N/A | |
| 2021-03-19 00:22 EST | News | HEXO, CSIQ, LAZR and SIG among premarket gainers | N/A | |
| 2021-03-12 08:56 EST | News | Orgenesis updates on Celyvir therapy collaboration deal | N/A | |
| 2021-03-11 04:16 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-09 21:35 EST | News | Orgenesis. (ORGS) CEO Vered Caplan on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-03-09 02:35 EST | News | Orgenesis and Cure Therapeutics partner to commercialize gene therapies for cancer treatment | N/A | |
| 2021-01-29 05:00 EST | News | Orgenesis: A Cell And Gene Therapy Disruptor With A Nice Risk Reward Profile | N/A | |
| 2020-11-26 21:07 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-24 13:07 EST | Analyst Rating | The Analyst Target Price has increased from $9 to $10. | Buy | |
| 2020-11-11 12:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-08 00:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 16:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 14:12 EST | News | Orgenesis reports Q3 results | N/A | |
| 2020-10-23 13:20 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-30 13:28 EST | News | Orgenesis to boost KYSLECEL commercialization through Koligo Therapeutics acquisition | N/A | |
| 2020-09-26 13:39 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 05:45 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-31 05:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 09:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-09 01:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-08 00:38 EST | News | Orgenesis reports Q2 results | N/A | |
| 2020-08-07 05:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 21:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 13:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 01:56 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 17:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 05:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 13:21 EST | Financials | Company financials have been released. | Neutral | |
About Orgenesis Inc (ORGS):
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. sThe company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. The company was incorporated in 2008 and is based in Germantown, Maryland.
General
- Name Orgenesis Inc
- Symbol ORGS
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 111
- Last Split Factor1:12
- Last Split Date2017-11-16
- Fiscal Year EndNovember
- IPO Date2012-03-12
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.orgenesis.com
View More
Valuation
- Trailing PE 23.98
- Price/Sales (Trailing 12 Mt.) 21.9
- Price/Book (Most Recent Quarter) 3.62
- Enterprise Value Revenue 20.67
View More
Financials
- Most Recent Quarter 2020-11-30
- Profit Margin 15%
- Operating Margin -1243%
- Return on Assets -70%
- Return on Equity -212%
- Revenue 7.65 million
- Earnings Per Share $0.29
- Revenue Per Share $0.36
- Gross Profit 7.65 million
- Quarterly Earnings Growth 105.6%
View More
Highlights
- Market Capitalization 170.61 million
- EBITDA -11295000
- Analyst Target Price $10
- Book Value Per Share $2.18
View More
Share Statistics
- Shares Outstanding 24.2 million
- Shares Float 21.42 million
- % Held by Insiders 1086%
- % Held by Institutions 26.47%
- Shares Short 336126
- Shares Short Prior Month 314456
- Short Ratio 2.22
- Short % of Float 2%
- Short % of Shares Outstanding 1%
View More
Technicals
- Beta 1.21
- 52 Week High $8.3
- 52 Week Low $2.76
- 50 Day Moving Average 7.09
- 200 Day Moving Average 5.5
View More
Dividends
- Dividend Date 2017-11-16
- ExDividend Date N/A
- Dividend Yield 0%
View More
Orgenesis Inc (ORGS) Dividend Calendar:
ORGS's last dividend payment was made to shareholders on November 16, 2017.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Orgenesis Inc (ORGS) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2021-02-28 | 2021-03-10 | -$2.14 | |||
| 2020-08-31 | 2020-11-05 | $1.73 million | -$0.11 | ||
| 2020-05-31 | 2020-08-06 | $N/A | -$0.39 | -$0.20 | -95% |
| 2020-02-29 | 2020-05-08 | $N/A | $4.23 | -$0.20 | 2215% |
| 2019-11-30 | 2019-12-31 | $N/A | -$0.44 | -$0.28 | -57.14% |
| 2019-08-31 | 2019-11-07 | $N/A | -$0.44 | -$0.28 | -57.14% |
| 2019-05-31 | 2019-08-13 | $N/A | -$0.36 | ||
| 2019-02-28 | 2019-05-08 | $419000 | -$0.55 | ||
| 2018-11-30 | 2019-02-13 | $5.8 million | -$0.39 | ||
| 2018-08-31 | 2018-10-12 | $6.23 million | -$0.35 | ||
| 2018-05-31 | 2018-07-17 | $3.99 million | -$0.20 | ||
| 2018-02-28 | 2018-04-16 | $2.64 million | -$0.52 | ||
| 2017-08-31 | 2017-11-01 | $2.56 million | -$0.21 | ||
| 2017-05-31 | 2017-05-31 | $2.3 million | -$0.06 | ||
| 2017-02-28 | 2017-02-28 | $1.85 million | -$0.97 | ||
| 2016-11-30 | 2016-11-30 | $1.9 million | -$0.29 | ||
| 2016-08-31 | 2016-08-31 | $1.85 million | -$0.29 | ||
| 2016-05-31 | 2016-05-31 | $1.13 million | -$0.43 | ||
| 2016-02-29 | 2016-02-29 | $1.52 million | $0.01 | ||
| 2015-11-30 | 2015-11-30 | $1.22 million | -$0.24 | ||
| 2015-08-31 | 2015-08-31 | $937000 | -$0.42 | ||
| 2015-05-31 | 2015-05-31 | $820000 | -$0.40 | ||
| 2015-02-28 | 2015-02-28 | $N/A | -$0.20 | ||
| 2014-11-30 | 2014-11-30 | $N/A | -$0.02 | ||
| 2014-08-31 | 2014-08-31 | $N/A | -$0.76 | ||
| 2014-05-31 | 2014-05-31 | $N/A | -$0.40 | ||
| 2014-02-28 | 2014-02-28 | $N/A | -$0.16 | ||
| 2013-11-30 | 2013-11-30 | $N/A | -$0.40 | ||
| 2013-08-31 | 2013-08-31 | $N/A | -$0.22 | ||
| 2013-05-31 | 2013-05-31 | $N/A | -$0.37 | ||
| 2013-02-28 | 2013-02-28 | $N/A | -$0.32 | ||
| 2012-11-30 | 2012-11-30 | $N/A | -$0.34 | ||
| 2012-08-31 | 2012-08-31 | $N/A | -$0.46 | ||
| 2012-05-31 | 2012-05-31 | $N/A | -$0.22 | ||
| 2012-02-29 | 2012-02-29 | $N/A | -$0.15 | ||
| 2011-11-30 | 2011-11-30 | $N/A | -$0.01 | ||
| 2011-08-31 | 2011-08-31 | $N/A | $0.00 | ||
| 2011-05-31 | 2011-05-31 | $N/A | $-0.00 | ||
| 2011-02-28 | 2011-02-28 | $N/A | $-0.00 | ||
| 2010-11-30 | 2010-11-30 | $-0.00 | |||
| 2010-08-31 | 2010-08-31 | $-0.00 |
Orgenesis Inc (ORGS) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Orgenesis Inc (ORGS) Chart:
Orgenesis Inc (ORGS) News:
Below you will find a list of latest news for Orgenesis Inc (ORGS) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Orgenesis Inc (ORGS) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 2.5 | 0.05 | CALL | 1 | 44 | 498.96 | FALSE | 0 | 0 |
| 2024-05-17 | 5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 7.5 | 0.04 | CALL | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 2.5 | 1.65 | PUT | 0 | 0 | 583.34 | TRUE | 0 | 0 |
| 2024-05-17 | 5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-06-21 | 2.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 2.5 | 0 | PUT | 0 | 0 | 331.31 | TRUE | 0 | 0 |
| 2024-06-21 | 5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-06-21 | 7.5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-08-16 | 2.5 | 0.1 | CALL | 0 | 27 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 5 | 0.28 | CALL | 0 | 3 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 2.5 | 0 | PUT | 0 | 0 | 557.28 | TRUE | 0 | 0 |
| 2024-08-16 | 5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-08-16 | 7.5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-11-15 | 2.5 | 0.05 | CALL | 0 | 13 | 0 | FALSE | 0 | 0 |
| 2024-11-15 | 5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-11-15 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-11-15 | 2.5 | 1.98 | PUT | 0 | 1 | 432.57 | TRUE | 0 | 0 |
| 2024-11-15 | 5 | 0 | PUT | 0 | 0 | 194.05 | TRUE | 0 | 0 |
| 2024-11-15 | 7.5 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
Latest ORGS Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 2:45 PM EST | 89 | $2.28 |
| Jun 13, 2022 2:45 PM EST | 100 | $2.28 |
| Jun 13, 2022 7:54 PM EST | 100 | $2.1 |
Orgenesis Inc (ORGS) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-05-26 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1460602/000117891320001584/0001178913-20-001584-index.htm |
| 2020-03-26 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1460602/000000000020002629/0000000000-20-002629-index.htm |
| 2020-10-22 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1460602/000090266420003712/0000902664-20-003712-index.htm |
| 2019-10-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1460602/000106299319003860/0001062993-19-003860-index.htm |
| 2019-11-04 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1460602/000106299319004133/0001062993-19-004133-index.htm |
| 2019-11-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1460602/000106299319004217/0001062993-19-004217-index.htm |
| 2019-11-12 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1460602/000106299319004265/0001062993-19-004265-index.htm |
| 2019-11-25 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1460602/000106299319004583/0001062993-19-004583-index.htm |
| 2019-11-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1460602/000106299319004613/0001062993-19-004613-index.htm |
| 2020-01-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1460602/000106299320000122/0001062993-20-000122-index.htm |
| 2020-01-13 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1460602/000106299320000130/0001062993-20-000130-index.htm |
| 2020-01-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1460602/000106299320000132/0001062993-20-000132-index.htm |
| 2020-01-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1460602/000106299320000215/0001062993-20-000215-index.htm |
| 2020-01-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1460602/000106299320000216/0001062993-20-000216-index.htm |
| 2020-01-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1460602/000106299320000217/0001062993-20-000217-index.htm |
| 2020-01-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1460602/000106299320000218/0001062993-20-000218-index.htm |
| 2020-01-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1460602/000106299320000263/0001062993-20-000263-index.htm |
| 2020-02-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1460602/000106299320000415/0001062993-20-000415-index.htm |
| 2020-02-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1460602/000106299320000903/0001062993-20-000903-index.htm |
| 2020-03-09 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1460602/000106299320001299/0001062993-20-001299-index.htm |
| 2020-03-18 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1460602/000106299320001393/0001062993-20-001393-index.htm |
| 2020-03-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1460602/000106299320001442/0001062993-20-001442-index.htm |
| 2020-03-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1460602/000106299320001443/0001062993-20-001443-index.htm |
| 2020-03-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1460602/000106299320001444/0001062993-20-001444-index.htm |
| 2020-03-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1460602/000106299320001445/0001062993-20-001445-index.htm |
| 2020-03-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1460602/000106299320001446/0001062993-20-001446-index.htm |
| 2020-03-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1460602/000106299320001447/0001062993-20-001447-index.htm |
| 2020-03-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1460602/000106299320001448/0001062993-20-001448-index.htm |
| 2020-03-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1460602/000106299320001449/0001062993-20-001449-index.htm |
| 2020-04-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1460602/000106299320001770/0001062993-20-001770-index.htm |
| 2020-04-14 | S-3/A | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1460602/000106299320001792/0001062993-20-001792-index.htm |
| 2020-04-14 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1460602/000106299320001800/0001062993-20-001800-index.htm |
| 2020-04-24 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1460602/000106299320001936/0001062993-20-001936-index.htm |
| 2020-04-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1460602/000106299320001938/0001062993-20-001938-index.htm |
| 2020-04-28 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1460602/000106299320001964/0001062993-20-001964-index.htm |
| 2020-05-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1460602/000106299320002161/0001062993-20-002161-index.htm |
| 2020-08-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1460602/000110465920095537/0001104659-20-095537-index.htm |
| 2020-01-28 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1460602/000117891320000210/0001178913-20-000210-index.htm |
| 2020-01-29 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1460602/000117891320000212/0001178913-20-000212-index.htm |
| 2020-05-26 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1460602/000117891320001584/0001178913-20-001584-index.htm |
| 2020-05-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1460602/000149315220008039/0001493152-20-008039-index.htm |
| 2020-08-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1460602/000149315220014863/0001493152-20-014863-index.htm |
| 2020-08-07 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1460602/000149315220014941/0001493152-20-014941-index.htm |
| 2020-09-23 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1460602/000149315220018242/0001493152-20-018242-index.htm |
| 2020-09-25 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1460602/000149315220018381/0001493152-20-018381-index.htm |
| 2020-10-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1460602/000149315220018712/0001493152-20-018712-index.htm |
| 2020-10-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1460602/000149315220019703/0001493152-20-019703-index.htm |
| 2020-11-03 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1460602/000149315220020399/0001493152-20-020399-index.htm |
| 2020-11-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1460602/000149315220020547/0001493152-20-020547-index.htm |
| 2020-01-29 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1460602/000171369520000001/0001713695-20-000001-index.htm |
| 2020-04-27 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1460602/999999999520000882/9999999995-20-000882-index.htm |